You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethylphenidate
Accession NumberDB00422  (APRD00657)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine. [PubChem]
Structure
Thumb
Synonyms
alpha-Phenyl-2-piperidineacetic acid methyl ester
Daytrana
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidylacetate
Methylphenidan
Methylphenidate
Methylphenidatum
Metilfenidato
MPH
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aptensio XRCapsule, extended release30 mg/1OralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRCapsule, extended release10 mg/1OralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRCapsule, extended release40 mg/1OralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRCapsule, extended release15 mg/1OralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRCapsule, extended release50 mg/1OralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRCapsule, extended release20 mg/1OralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRCapsule, extended release60 mg/1OralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
BiphentinCapsule, extended release20 mgOralPurdue Pharma2006-08-01Not applicableCanada
BiphentinCapsule, extended release50 mgOralPurdue Pharma2006-08-01Not applicableCanada
BiphentinCapsule, extended release10 mgOralPurdue Pharma2006-08-01Not applicableCanada
BiphentinCapsule, extended release60 mgOralPurdue Pharma2006-08-01Not applicableCanada
BiphentinCapsule, extended release30 mgOralPurdue Pharma2006-08-01Not applicableCanada
BiphentinCapsule, extended release80 mgOralPurdue Pharma2007-03-09Not applicableCanada
BiphentinCapsule, extended release40 mgOralPurdue Pharma2006-08-01Not applicableCanada
BiphentinCapsule, extended release15 mgOralPurdue Pharma2006-08-01Not applicableCanada
ConcertaTablet, extended release36 mg/1OralPhysicians Total Care, Inc.2003-03-20Not applicableUs
ConcertaTablet, extended release36 mgOralJanssen Inc2003-07-23Not applicableCanada
ConcertaTablet, extended release27 mg/1OralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
ConcertaTablet, extended release18 mg/1OralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
ConcertaTablet, extended release54 mg/1OralPhysicians Total Care, Inc.2003-05-08Not applicableUs
ConcertaTablet, extended release54 mgOralJanssen Inc2003-07-23Not applicableCanada
ConcertaTablet, extended release18 mg/1OralPhysicians Total Care, Inc.2003-03-21Not applicableUs
ConcertaTablet, extended release36 mg/1OralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
ConcertaTablet, extended release27 mg/1OralPhysicians Total Care, Inc.2003-11-13Not applicableUs
ConcertaTablet, extended release27 mgOralJanssen Inc2005-01-06Not applicableCanada
ConcertaTablet, extended release18 mgOralJanssen Inc2003-07-23Not applicableCanada
ConcertaTablet, extended release54 mg/1OralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
DaytranaPatch30 mg/9hTransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
DaytranaPatch10 mg/9hTransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
DaytranaPatch15 mg/9hTransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
DaytranaPatch20 mg/9hTransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
Metadate CDCapsule, extended release40 mg/1OralUnither Manufacturing, LLC2006-03-21Not applicableUs
Metadate CDCapsule, extended release50 mg/1OralPhysicians Total Care, Inc.2011-03-02Not applicableUs
Metadate CDCapsule, extended release50 mg/1OralUnither Manufacturing, LLC2006-03-21Not applicableUs
Metadate CDCapsule, extended release10 mg/1OralUnither Manufacturing, LLC2003-08-12Not applicableUs
Metadate CDCapsule, extended release60 mg/1OralUnither Manufacturing, LLC2006-03-21Not applicableUs
Metadate CDCapsule, extended release20 mg/1OralUnither Manufacturing, LLC2003-02-18Not applicableUs
Metadate CDCapsule, extended release20 mg/1OralPhysicians Total Care, Inc.2002-12-23Not applicableUs
Metadate CDCapsule, extended release10 mg/1OralPhysicians Total Care, Inc.2005-08-26Not applicableUs
Metadate CDCapsule, extended release30 mg/1OralPhysicians Total Care, Inc.2005-08-26Not applicableUs
Metadate CDCapsule, extended release30 mg/1OralUnither Manufacturing, LLC2003-07-22Not applicableUs
MethylinSolution10 mg/5mLOralShionogi Inc.2010-11-01Not applicableUs
MethylinTablet, chewable2.5 mg/1OralShionogi Inc.2010-11-01Not applicableUs
MethylinTablet, chewable5 mg/1OralShionogi Inc.2010-11-01Not applicableUs
MethylinTablet, chewable10 mg/1OralShionogi Inc.2010-11-01Not applicableUs
MethylinSolution5 mg/5mLOralShionogi Inc.2010-11-01Not applicableUs
MethylphenidateTablet10 mgOralPro Doc Limitee2009-06-12Not applicableCanada
MethylphenidateTablet20 mgOralPro Doc Limitee2009-06-12Not applicableCanada
MethylphenidateCapsule, extended release20 mg/1OralSandoz Inc2015-11-24Not applicableUs
MethylphenidateCapsule, extended release30 mg/1OralSandoz Inc2015-11-24Not applicableUs
MethylphenidateTablet5 mgOralPro Doc Limitee2009-06-12Not applicableCanada
MethylphenidateCapsule, extended release40 mg/1OralSandoz Inc2015-11-24Not applicableUs
Methylphenidate HCl Oral SolutionSolution5 mg/5mLOralMallinckrodt, Inc.2013-08-01Not applicableUs
Methylphenidate HCl Oral SolutionSolution10 mg/5mLOralMallinckrodt, Inc.2013-08-01Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralSandoz Inc1955-12-31Not applicableUs
Methylphenidate HydrochlorideTablet27 mg/1OralAmerican Health Packaging2014-09-04Not applicableUs
Methylphenidate HydrochlorideTablet54 mg/1OralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate HydrochlorideTablet18 mg/1OralAvera Mc Kennan Hospital2015-11-04Not applicableUs
Methylphenidate HydrochlorideTablet18 mg/1OralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralSandoz Inc1955-12-31Not applicableUs
Methylphenidate HydrochlorideTablet18 mg/1OralPhysicians Total Care, Inc.2011-06-01Not applicableUs
Methylphenidate HydrochlorideTablet36 mg/1OralAmerican Health Packaging2014-09-04Not applicableUs
Methylphenidate HydrochlorideTablet27 mg/1OralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralSandoz Inc1955-12-31Not applicableUs
Methylphenidate HydrochlorideTablet27 mg/1OralPhysicians Total Care, Inc.2011-06-01Not applicableUs
Methylphenidate HydrochlorideTablet54 mg/1OralAmerican Health Packaging2014-09-04Not applicableUs
Methylphenidate HydrochlorideTablet36 mg/1OralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1Oralbryant ranch prepack1955-12-31Not applicableUs
Methylphenidate HydrochlorideTablet18 mg/1OralAmerican Health Packaging2015-01-15Not applicableUs
Methylphenidate Hydrochloride CDCapsule, extended release40 mg/1OralKremers Urban Pharmaceuticals Inc.2006-03-21Not applicableUs
Methylphenidate Hydrochloride CDCapsule, extended release10 mg/1OralKremers Urban Pharmaceuticals Inc.2003-08-12Not applicableUs
Methylphenidate Hydrochloride CDCapsule, extended release50 mg/1OralKremers Urban Pharmaceuticals Inc.2006-03-21Not applicableUs
Methylphenidate Hydrochloride CDCapsule, extended release20 mg/1OralKremers Urban Pharmaceuticals Inc.2003-02-18Not applicableUs
Methylphenidate Hydrochloride CDCapsule, extended release60 mg/1OralKremers Urban Pharmaceuticals Inc.2006-03-21Not applicableUs
Methylphenidate Hydrochloride CDCapsule, extended release30 mg/1OralKremers Urban Pharmaceuticals Inc.2003-07-22Not applicableUs
Methylphenidate Hydrochloride SRTablet, film coated, extended release20 mg/1OralSandoz Inc1982-03-31Not applicableUs
Methylphenidate Tab 10mgTablet10 mgOralTechnilab Pharma Inc.1996-08-061999-01-22Canada
Methylphenidate Tab 20mgTablet20 mgOralTechnilab Pharma Inc.1996-08-061999-01-22Canada
Novo-methylphenidateTablet5.00 mgOralNovopharm LimitedNot applicableNot applicableCanada
Novo-methylphenidateTablet10.00 mgOralNovopharm LimitedNot applicableNot applicableCanada
Novo-methylphenidateTablet20.00 mgOralNovopharm LimitedNot applicableNot applicableCanada
PHL-methylphenidateTablet5 mgOralPharmel Inc2003-01-07Not applicableCanada
PHL-methylphenidateTablet20 mgOralPharmel Inc2003-04-21Not applicableCanada
PHL-methylphenidateTablet10 mgOralPharmel Inc2003-04-21Not applicableCanada
PMS-methylphenidateTablet10 mgOralPharmascience Inc1990-12-31Not applicableCanada
PMS-methylphenidateTablet20 mgOralPharmascience Inc1990-12-31Not applicableCanada
PMS-methylphenidateTablet5 mgOralPharmascience Inc1997-10-24Not applicableCanada
PMS-methylphenidate ERTablet, extended release36 mgOralPharmascience Inc2014-03-03Not applicableCanada
PMS-methylphenidate ERTablet, extended release54 mgOralPharmascience Inc2014-03-03Not applicableCanada
PMS-methylphenidate ERTablet, extended release18 mgOralPharmascience Inc2014-03-03Not applicableCanada
PMS-methylphenidate ERTablet, extended release27 mgOralPharmascience Inc2014-03-03Not applicableCanada
Quillichew ERTablet, Chewable, Extended Release20 mg/1OralNext Wave Pharmaceuticals, Inc.2016-02-17Not applicableUs
Quillichew ERTablet, Chewable, Extended Release30 mg/1OralNext Wave Pharmaceuticals, Inc.2016-02-17Not applicableUs
Quillichew ERTablet, Chewable, Extended Release40 mg/1OralNext Wave Pharmaceuticals, Inc.2016-02-17Not applicableUs
Quillivant XRPowder, for suspension900 mg/180mLOralNext Wave Pharmaceuticals, Inc.2012-10-01Not applicableUs
Quillivant XRPowder, for suspension300 mg/60mLOralNext Wave Pharmaceuticals, Inc.2012-10-01Not applicableUs
Quillivant XRPowder, for suspension600 mg/120mLOralNext Wave Pharmaceuticals, Inc.2012-10-01Not applicableUs
Quillivant XRPowder, for suspension750 mg/150mLOralNext Wave Pharmaceuticals, Inc.2013-01-04Not applicableUs
Ratio-methylphenidateTablet10 mgOralTeva Canada Limited1998-01-22Not applicableCanada
Ratio-methylphenidateTablet20 mgOralTeva Canada Limited1998-01-22Not applicableCanada
Ratio-methylphenidateTablet5 mgOralTeva Canada Limited2003-05-01Not applicableCanada
RitalinTablet20 mg/1OralPhysicians Total Care, Inc.2000-03-10Not applicableUs
RitalinTablet5 mg/1OralNovartis Pharmaceuticals Corporation1955-12-31Not applicableUs
RitalinTablet10 mg/1OralNovartis Pharmaceuticals Corporation1955-12-31Not applicableUs
RitalinTablet20 mg/1OralNovartis Pharmaceuticals Corporation1955-12-31Not applicableUs
Ritalin 10mgTablet10 mgOralNovartis Pharmaceuticals Canada Inc1956-12-31Not applicableCanada
Ritalin 20mgTablet20 mgOralNovartis Pharmaceuticals Canada Inc1958-12-31Not applicableCanada
Ritalin LACapsule, extended release60 mg/1OralNovartis Pharmaceuticals Corporation2015-02-01Not applicableUs
Ritalin LACapsule, extended release20 mg/1OralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin LACapsule, extended release30 mg/1OralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin LACapsule, extended release40 mg/1OralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin LACapsule, extended release10 mg/1OralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin-SR Tab 20mgTablet, extended release20 mgOralNovartis Pharmaceuticals Canada Inc1984-12-31Not applicableCanada
Sandoz MethylphenidateTablet10 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz MethylphenidateTablet20 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Methylphenidate SRTablet, extended release20 mgOralSandoz Canada Incorporated2008-12-23Not applicableCanada
Teva-methylphenidate ER-CTablet, extended release54 mgOralTeva Canada Limited2010-01-20Not applicableCanada
Teva-methylphenidate ER-CTablet, extended release18 mgOralTeva Canada Limited2010-01-20Not applicableCanada
Teva-methylphenidate ER-CTablet, extended release27 mgOralTeva Canada Limited2010-01-20Not applicableCanada
Teva-methylphenidate ER-CTablet, extended release36 mgOralTeva Canada Limited2010-01-20Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-methylphenidateTablet20 mgOralApotex Inc2004-11-02Not applicableCanada
Apo-methylphenidateTablet5 mgOralApotex Inc2006-02-01Not applicableCanada
Apo-methylphenidateTablet10 mgOralApotex Inc2004-11-02Not applicableCanada
Apo-methylphenidate ERTablet, extended release36 mgOralApotex Inc2016-07-22Not applicableCanada
Apo-methylphenidate ERTablet, extended release54 mgOralApotex Inc2016-07-22Not applicableCanada
Apo-methylphenidate ERTablet, extended release18 mgOralApotex Inc2016-07-22Not applicableCanada
Apo-methylphenidate ERTablet, extended release27 mgOralApotex Inc2016-07-22Not applicableCanada
Apo-methylphenidate SRTablet, extended release20 mgOralApotex Inc2005-04-27Not applicableCanada
Metadate ERTablet, extended release20 mg/1OralUpstate Pharma, LLC2014-11-01Not applicableUs
Metadate ERTablet, extended release20 mg/1OralUnither Manufacturing, LLC1988-06-01Not applicableUs
MethylphenidateTablet5 mg/1OralPhysicians Total Care, Inc.2009-05-14Not applicableUs
MethylphenidateSolution5 mg/5mLOralKvk Tech, Inc.2016-11-21Not applicableUs
MethylphenidateTablet5 mg/1OralSTAT Rx USA LLC1997-08-29Not applicableUs
MethylphenidateTablet20 mg/1OralPhysicians Total Care, Inc.2007-10-16Not applicableUs
MethylphenidateSolution10 mg/5mLOralKvk Tech, Inc.2016-11-21Not applicableUs
MethylphenidateTablet10 mg/1OralPhysicians Total Care, Inc.2005-03-24Not applicableUs
Methylphenidate HydrochlorideSolution5 mg/5mLOralCaraco Pharmaceutical Laboratories, Ltd.2012-03-01Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralUpstate Pharma, LLC2014-11-01Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralCore Pharma, Llc2014-04-07Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release30 mg/1OralActavis Pharma, Inc.2012-01-03Not applicableUs
Methylphenidate HydrochlorideSolution5 mg/5mLOralBreckenridge Pharmaceutical, Inc.2010-07-01Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralAlvogen Inc.2016-11-14Not applicableUs
Methylphenidate HydrochlorideTablet, extended release18 mg/1OralKremers Urban Pharmaceuticals Inc.2013-07-10Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release20 mg/1OralAmerican Health Packaging2014-12-012016-10-13Us
Methylphenidate HydrochlorideTablet, chewable5 mg/1OralGAVIS Pharmaceuticals, LLC2015-04-06Not applicableUs
Methylphenidate HydrochlorideSolution5 mg/5mLOralNovel Laboratories, Inc.2015-08-14Not applicableUs
Methylphenidate HydrochlorideTablet, extended release10 mg/1OralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release30 mg/1OralCore Pharma, Llc2016-09-20Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release40 mg/1OralActavis South Atlantic LLC2012-01-03Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralGAVIS Pharmaceuticals, LLC2016-01-20Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralUnither Manufacturing, LLC1979-04-04Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralCamber Pharmaceuticals Inc.2015-10-01Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralSun Pharmaceutical Industries, Inc.2013-08-16Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1Oralbryant ranch prepack2010-02-01Not applicableUs
Methylphenidate HydrochlorideSolution5 mg/5mLOralGAVIS Pharmaceuticals, LLC2015-12-15Not applicableUs
Methylphenidate HydrochlorideTablet, extended release20 mg/1OralCounty Line Pharmaceuticals, LLC2016-02-29Not applicableUs
Methylphenidate HydrochlorideTablet, extended release36 mg/1OralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralQualitest Pharmaceuticals2014-09-23Not applicableUs
Methylphenidate HydrochlorideSolution10 mg/5mLOralNostrum Laboratories, Inc.2016-01-06Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralActavis Pharma, Inc.1997-08-29Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release40 mg/1OralActavis Pharma, Inc.2012-01-03Not applicableUs
Methylphenidate HydrochlorideSolution10 mg/5mLOralBreckenridge Pharmaceutical, Inc.2010-07-01Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralAlvogen Inc.2016-11-14Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release40 mg/1OralCore Pharma, Llc2016-09-20Not applicableUs
Methylphenidate HydrochlorideTablet, extended release27 mg/1OralKremers Urban Pharmaceuticals Inc.2013-07-10Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralNovel Laboratories, Inc.2015-11-13Not applicableUs
Methylphenidate HydrochlorideTablet, chewable10 mg/1OralGAVIS Pharmaceuticals, LLC2015-04-06Not applicableUs
Methylphenidate HydrochlorideSolution10 mg/5mLOralNovel Laboratories, Inc.2015-08-14Not applicableUs
Methylphenidate HydrochlorideTablet, extended release20 mg/1OralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralAmerican Health Packaging2014-08-19Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralGAVIS Pharmaceuticals, LLC2016-01-20Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralUnither Manufacturing, LLC1979-04-04Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release20 mg/1OralAmerican Health Packaging2016-06-01Not applicableUs
Methylphenidate HydrochlorideTablet, chewable2.5 mg/1OralNovel Laboratories, Inc.2015-02-25Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralSun Pharmaceutical Industries, Inc.2013-08-16Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralUpstate Pharma, LLC2014-11-01Not applicableUs
Methylphenidate HydrochlorideSolution10 mg/5mLOralGAVIS Pharmaceuticals, LLC2015-12-15Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralCore Pharma, Llc2014-04-07Not applicableUs
Methylphenidate HydrochlorideTablet, extended release54 mg/1OralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate HydrochlorideSolution5 mg/5mLOralTris Pharma Inc2015-03-04Not applicableUs
Methylphenidate HydrochlorideSolution5 mg/5mLOralNostrum Laboratories, Inc.2016-01-06Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralActavis Pharma, Inc.1997-08-29Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-09-15Not applicableUs
Methylphenidate HydrochlorideTablet, chewable5 mg/1OralTedor Pharma Inc.2016-11-21Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralCamber Pharmaceuticals Inc.2015-10-01Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release20 mg/1OralActavis South Atlantic LLC2012-01-03Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release20 mg/1OralAvera Mc Kennan Hospital2015-11-04Not applicableUs
Methylphenidate HydrochlorideTablet, extended release18 mg/1OralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralQualitest Pharmaceuticals2014-09-23Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release50 mg/1OralCore Pharma, Llc2016-09-20Not applicableUs
Methylphenidate HydrochlorideTablet, extended release20 mg/1OralPhysicians Total Care, Inc.1994-12-16Not applicableUs
Methylphenidate HydrochlorideTablet, extended release36 mg/1OralKremers Urban Pharmaceuticals Inc.2013-09-23Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralNovel Laboratories, Inc.2015-11-13Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralAmerican Health Packaging2014-08-19Not applicableUs
Methylphenidate HydrochlorideTablet, extended release18 mg/1OralAvera Mc Kennan Hospital2015-03-06Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release10 mg/1OralCore Pharma, Llc2016-09-20Not applicableUs
Methylphenidate HydrochlorideTablet, chewable5 mg/1OralNovel Laboratories, Inc.2015-02-25Not applicableUs
Methylphenidate HydrochlorideSolution10 mg/5mLOralCaraco Pharmaceutical Laboratories, Ltd.2012-03-01Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralUpstate Pharma, LLC2014-11-01Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralCore Pharma, Llc2014-04-07Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release20 mg/1OralActavis Pharma, Inc.2012-01-03Not applicableUs
Methylphenidate HydrochlorideSolution10 mg/5mLOralTris Pharma Inc2015-03-04Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralAlvogen Inc.2016-11-142016-11-18Us
Methylphenidate HydrochlorideTablet5 mg/1OralGAVIS Pharmaceuticals, LLC2016-01-20Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralUnither Manufacturing, LLC1977-12-23Not applicableUs
Methylphenidate HydrochlorideTablet, chewable10 mg/1OralTedor Pharma Inc.2016-11-21Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralCamber Pharmaceuticals Inc.2015-10-01Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release30 mg/1OralActavis South Atlantic LLC2012-01-03Not applicableUs
Methylphenidate HydrochlorideTablet, extended release54 mg/1OralKremers Urban Pharmaceuticals Inc.2013-09-23Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralNovel Laboratories, Inc.2015-11-13Not applicableUs
Methylphenidate HydrochlorideTablet, extended release10 mg/1OralCounty Line Pharmaceuticals, LLC2016-02-29Not applicableUs
Methylphenidate HydrochlorideTablet, extended release27 mg/1OralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate HydrochlorideTablet10 mg/1OralQualitest Pharmaceuticals2014-09-23Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release60 mg/1OralCore Pharma, Llc2016-09-20Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralActavis Pharma, Inc.1997-08-29Not applicableUs
Methylphenidate HydrochlorideTablet5 mg/1OralSun Pharmaceutical Industries, Inc.2013-08-16Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralAmerican Health Packaging2014-08-19Not applicableUs
Methylphenidate HydrochlorideTablet, chewable2.5 mg/1OralGAVIS Pharmaceuticals, LLC2015-04-06Not applicableUs
Methylphenidate HydrochlorideTablet20 mg/1OralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate HydrochlorideCapsule, extended release20 mg/1OralCore Pharma, Llc2016-09-20Not applicableUs
Methylphenidate HydrochlorideTablet, chewable10 mg/1OralNovel Laboratories, Inc.2015-02-25Not applicableUs
Methylphenidate Hydrochloride (cd)Capsule, extended release50 mg/1OralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)Capsule, extended release30 mg/1OralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)Capsule, extended release60 mg/1OralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)Capsule, extended release40 mg/1OralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)Capsule, extended release10 mg/1OralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)Capsule, extended release10 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Methylphenidate Hydrochloride (cd)Capsule, extended release20 mg/1OralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)Capsule, extended release30 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Methylphenidate Hydrochloride (la)Capsule, extended release30 mg/1OralTeva Pharmaceuticals USA Inc2012-07-16Not applicableUs
Methylphenidate Hydrochloride (la)Capsule, extended release40 mg/1OralMayne Pharma2016-08-03Not applicableUs
Methylphenidate Hydrochloride (la)Capsule, extended release40 mg/1OralTeva Pharmaceuticals USA Inc2012-07-16Not applicableUs
Methylphenidate Hydrochloride (la)Capsule, extended release20 mg/1OralMayne Pharma2016-08-03Not applicableUs
Methylphenidate Hydrochloride (la)Capsule, extended release20 mg/1OralTeva Pharmaceuticals USA Inc2012-07-16Not applicableUs
Methylphenidate Hydrochloride (la)Capsule, extended release30 mg/1OralMayne Pharma2016-08-03Not applicableUs
Methylphenidate Hydrochloride ERTablet, extended release10 mg/1OralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloride ERTablet, extended release20 mg/1OralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloride Extended ReleaseTablet20 mg/1OralKvk Tech, Inc.2015-06-09Not applicableUs
Methylphenidate Hydrochloride Extended ReleaseTablet10 mg/1OralKvk Tech, Inc.2015-06-09Not applicableUs
Methylphenidate Hydrochloride Extended-releaseCapsule40 mg/1OralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releaseTablet54 mg/1OralMallinckrodt, Inc.2012-06-30Not applicableUs
Methylphenidate Hydrochloride Extended-releaseCapsule50 mg/1OralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releaseCapsule10 mg/1OralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releaseTablet27 mg/1OralMallinckrodt, Inc.2012-06-30Not applicableUs
Methylphenidate Hydrochloride Extended-releaseCapsule60 mg/1OralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releaseCapsule20 mg/1OralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releaseTablet36 mg/1OralMallinckrodt, Inc.2012-06-30Not applicableUs
Methylphenidate Hydrochloride Extended-releaseCapsule30 mg/1OralMallinckrodt, Inc.2015-09-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Equasym XLNot Available
Medikinet XLNot Available
MetadateNot Available
QuillivantNot Available
RiphenidateNot Available
Rubifen SRNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Methylphenidate Hydrochloride
Thumb
  • InChI Key: JUMYIBMBTDDLNG-UHFFFAOYNA-N
  • Monoisotopic Mass: 269.118256596
  • Average Mass: 269.767
DBSALT000117
Categories
UNII207ZZ9QZ49
CAS number113-45-1
WeightAverage: 233.3062
Monoisotopic: 233.141578857
Chemical FormulaC14H19NO2
InChI KeyDUGOZIWVEXMGBE-UHFFFAOYSA-N
InChI
InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
IUPAC Name
methyl 2-phenyl-2-(piperidin-2-yl)acetate
SMILES
COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Pharmacology
IndicationFor use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.
Structured Indications
PharmacodynamicsMethylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Methylphenidate also blocks the reuptake of norepinephrine and dopamine. Its mechanisms appear to be similar to those of dextroamphetamine. Furthermore, it is a racemic mixture comprised of the d- and l-threo enantiomers. The d-threo enantiomer is more pharmacologically active than the l-threo enantiomer.
Mechanism of actionMethylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent dopamine transporterProteinyes
inhibitor
HumanQ01959 details
Sodium-dependent noradrenaline transporterProteinunknown
inhibitor
HumanP23975 details
Sodium-dependent serotonin transporterProteinunknown
inhibitor
HumanP31645 details
Related Articles
AbsorptionReadily absorbed in a biphasic manner when orally administered (tablets) to children diagnosed with ADHD and to healthy adults. In children and adults males, after administration of a single oral dose of Ritalin LA and Ritalin given in two doses 4 hours apart, peak plasma concentration is reached approximately 2 hours for the first phase and 5-6 hours for the second phase. The absolute oral bioavailability of methylphenidate in children was 22±8% for d-methylphenidate and 5±3% for l-methylphenidate. These low values suggest that methylphenidate is highly metabolized presystemically.
Volume of distribution

d-methylphenidate = 2.65 L/kg;
l-methylphenidate = 1.80 L/kg;

Protein bindingBinding to plasma proteins is low (10%-33%).
Metabolism

Methylphenidate is hepatically metabolized. More specifically, it is rapidly and extensively metabolized by carboxylesterase CES1A1. Via this enzyme, methylphenidate undergoes de-esterification to ritalinic acid (a-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity.

Route of eliminationAfter oral administration of an immediate release formulation of methylphenidate, 78%-97% of the dose is excreted in the urine and 1%-3% in the feces in the form of metabolites within 48-96 hours. Only small quantities (<1%) of unchanged methylphenidate appear in the urine. Most of the dose is excreted in the urine as ritalinic acid (60%-86%), the remainder being accounted for by minor metabolites.
Half lifed-methylphenidate = 3-4 hours; l-methylphenidate = 1-3 hours; Ritalinic acid = 3-4 hours;
Clearance

Systemic clearance for Ritalin LA and Ritalin tablets is as follows:
d-methylphenidate= 0.40±0.12 L/h/kg;
l-methylphenidate = 0.73±0.28 L/h/kg;

ToxicitySymptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Methylphenidate.Experimental
AbirateroneThe serum concentration of Methylphenidate can be increased when it is combined with Abiraterone.Approved
AcebutololMethylphenidate may decrease the antihypertensive activities of Acebutolol.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Methylphenidate.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methylphenidate.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methylphenidate.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Methylphenidate.Approved
AliskirenMethylphenidate may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololMethylphenidate may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
Aluminum phosphateAluminum phosphate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
AmantadineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amantadine.Approved
AmbrisentanMethylphenidate may decrease the antihypertensive activities of Ambrisentan.Approved, Investigational
AmineptineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe metabolism of Methylphenidate can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methylphenidate.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amitriptyline.Approved
AmlodipineMethylphenidate may decrease the antihypertensive activities of Amlodipine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Methylphenidate.Experimental
ApomorphineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Apomorphine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.Approved, Investigational
ArtemetherThe metabolism of Methylphenidate can be decreased when combined with Artemether.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methylphenidate.Approved
AtenololMethylphenidate may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Methylphenidate can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Methylphenidate.Vet Approved
BenazeprilMethylphenidate may decrease the antihypertensive activities of Benazepril.Approved, Investigational
BendroflumethiazideMethylphenidate may decrease the antihypertensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Methylphenidate.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Methylphenidate.Investigational
BepridilMethylphenidate may decrease the antihypertensive activities of Bepridil.Approved, Withdrawn
BetaxololMethylphenidate may decrease the antihypertensive activities of Betaxolol.Approved
BethanidineMethylphenidate may decrease the antihypertensive activities of Bethanidine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Methylphenidate.Investigational
BimatoprostMethylphenidate may decrease the antihypertensive activities of Bimatoprost.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
BisoprololMethylphenidate may decrease the antihypertensive activities of Bisoprolol.Approved
BosentanMethylphenidate may decrease the antihypertensive activities of Bosentan.Approved, Investigational
BretyliumMethylphenidate may decrease the antihypertensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methylphenidate.Approved
BrimonidineMethylphenidate may decrease the antihypertensive activities of Brimonidine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Methylphenidate.Investigational
BupranololMethylphenidate may decrease the antihypertensive activities of Bupranolol.Approved
BupropionThe metabolism of Methylphenidate can be decreased when combined with Bupropion.Approved
Calcium carbonateCalcium carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
CandesartanMethylphenidate may decrease the antihypertensive activities of Candesartan.Approved
CandoxatrilMethylphenidate may decrease the antihypertensive activities of Candoxatril.Experimental
CaptoprilMethylphenidate may decrease the antihypertensive activities of Captopril.Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Methylphenidate.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Methylphenidate.Withdrawn
CarteololMethylphenidate may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMethylphenidate may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Methylphenidate can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololMethylphenidate may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
ChloroquineThe metabolism of Methylphenidate can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideMethylphenidate may decrease the antihypertensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenidate.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylphenidate.Approved, Withdrawn
ChlorthalidoneMethylphenidate may decrease the antihypertensive activities of Chlorthalidone.Approved
CholecalciferolThe metabolism of Methylphenidate can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilMethylphenidate may decrease the antihypertensive activities of Cilazapril.Approved
CimetidineCimetidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
CinacalcetThe metabolism of Methylphenidate can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Methylphenidate can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Methylphenidate can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Methylphenidate can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Clonidine.Approved
ClotrimazoleThe metabolism of Methylphenidate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenidate.Approved
CobicistatThe serum concentration of Methylphenidate can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Methylphenidate can be decreased when combined with Cocaine.Approved, Illicit
CryptenamineMethylphenidate may decrease the antihypertensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Cyclobenzaprine.Approved
CyclothiazideMethylphenidate may decrease the antihypertensive activities of Cyclothiazide.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenidate.Approved
DarifenacinThe metabolism of Methylphenidate can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Methylphenidate can be increased when it is combined with Darunavir.Approved
DebrisoquinMethylphenidate may decrease the antihypertensive activities of Debrisoquin.Approved
DelavirdineThe metabolism of Methylphenidate can be decreased when combined with Delavirdine.Approved
DeserpidineMethylphenidate may decrease the antihypertensive activities of Deserpidine.Approved
DesfluraneMethylphenidate may increase the hypertensive activities of Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Desipramine.Approved
DiazoxideMethylphenidate may decrease the antihypertensive activities of Diazoxide.Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Methylphenidate.Approved
DihydralazineMethylphenidate may decrease the antihypertensive activities of Dihydralazine.Investigational
DiltiazemMethylphenidate may decrease the antihypertensive activities of Diltiazem.Approved
DiphenhydramineThe metabolism of Methylphenidate can be decreased when combined with Diphenhydramine.Approved
DorzolamideMethylphenidate may decrease the antihypertensive activities of Dorzolamide.Approved
DosulepinThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Dosulepin.Approved
DoxazosinMethylphenidate may decrease the antihypertensive activities of Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Doxepin.Approved
DronedaroneThe metabolism of Methylphenidate can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate.Approved, Vet Approved
DuloxetineThe metabolism of Methylphenidate can be decreased when combined with Duloxetine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Methylphenidate.Investigational
EfonidipineMethylphenidate may decrease the antihypertensive activities of Efonidipine.Approved
EliglustatThe metabolism of Methylphenidate can be decreased when combined with Eliglustat.Approved
EnalaprilMethylphenidate may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatMethylphenidate may decrease the antihypertensive activities of Enalaprilat.Approved
EnfluraneMethylphenidate may increase the hypertensive activities of Enflurane.Approved, Vet Approved
EpinastineEpinastine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
EpoprostenolMethylphenidate may decrease the antihypertensive activities of Epoprostenol.Approved
EprosartanMethylphenidate may decrease the antihypertensive activities of Eprosartan.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Esmirtazapine.Investigational
EsomeprazoleEsomeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methylphenidate.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Methylphenidate.Withdrawn
FamotidineFamotidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
FelodipineMethylphenidate may decrease the antihypertensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methylphenidate.Approved, Illicit, Withdrawn
FenoldopamMethylphenidate may decrease the antihypertensive activities of Fenoldopam.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylphenidate.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Methylphenidate.Investigational
FluoxetineThe metabolism of Methylphenidate can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenidate.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate.Approved
FluvoxamineThe metabolism of Methylphenidate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilMethylphenidate may decrease the antihypertensive activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Methylphenidate.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Methylphenidate.Approved, Vet Approved
GuanabenzMethylphenidate may decrease the antihypertensive activities of Guanabenz.Approved
GuanadrelMethylphenidate may decrease the antihypertensive activities of Guanadrel.Approved
GuanethidineMethylphenidate may decrease the antihypertensive activities of Guanethidine.Approved
GuanfacineMethylphenidate may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.Approved
HalothaneMethylphenidate may increase the hypertensive activities of Halothane.Approved, Vet Approved
HexamethoniumMethylphenidate may decrease the antihypertensive activities of Hexamethonium.Experimental
HydracarbazineHydracarbazine may increase the hypertensive activities of Methylphenidate.Approved
HydralazineMethylphenidate may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideMethylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideMethylphenidate may decrease the antihypertensive activities of Hydroflumethiazide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenidate.Approved
ImidaprilMethylphenidate may decrease the antihypertensive activities of Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine.Approved
IndapamideMethylphenidate may decrease the antihypertensive activities of Indapamide.Approved
IndenololMethylphenidate may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Methylphenidate can be decreased when combined with Indinavir.Approved
IndoraminMethylphenidate may decrease the antihypertensive activities of Indoramin.Withdrawn
Ioflupane I-123Methylphenidate may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the hypertensive activities of Methylphenidate.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Methylphenidate.Withdrawn
IrbesartanMethylphenidate may decrease the antihypertensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Methylphenidate.Approved
IsofluraneMethylphenidate may increase the hypertensive activities of Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Methylphenidate can be decreased when combined with Isoniazid.Approved
IsradipineMethylphenidate may decrease the antihypertensive activities of Isradipine.Approved
KetanserinMethylphenidate may decrease the antihypertensive activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Methylphenidate can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolMethylphenidate may decrease the antihypertensive activities of Labetalol.Approved
LacidipineMethylphenidate may decrease the antihypertensive activities of Lacidipine.Approved
LansoprazoleLansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
LatanoprostMethylphenidate may decrease the antihypertensive activities of Latanoprost.Approved, Investigational
LercanidipineMethylphenidate may decrease the antihypertensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Levodopa.Approved
LisinoprilMethylphenidate may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Methylphenidate.Approved
LofexidineMethylphenidate may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Methylphenidate can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Methylphenidate can be decreased when combined with Lorcaserin.Approved
LosartanMethylphenidate may decrease the antihypertensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenidate.Approved
LumefantrineThe metabolism of Methylphenidate can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.Approved
MacitentanMethylphenidate may decrease the antihypertensive activities of Macitentan.Approved
MagaldrateMagaldrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Withdrawn
Magnesium carbonateMagnesium carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
Magnesium hydroxideMagnesium hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
Magnesium oxideMagnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
ManidipineMethylphenidate may decrease the antihypertensive activities of Manidipine.Approved
MebanazineMebanazine may increase the hypertensive activities of Methylphenidate.Withdrawn
MecamylamineMethylphenidate may decrease the antihypertensive activities of Mecamylamine.Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Methylphenidate.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methylphenidate.Approved
MethadoneThe metabolism of Methylphenidate can be decreased when combined with Methadone.Approved
MethanthelineMethantheline can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate.Approved
MethoxyfluraneMethylphenidate may increase the hypertensive activities of Methoxyflurane.Approved, Vet Approved
MethyldopaMethylphenidate may decrease the antihypertensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Methylphenidate.Investigational
MetiamideMetiamide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Experimental
MetipranololMethylphenidate may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneMethylphenidate may decrease the antihypertensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Methylphenidate.Approved, Investigational
MetyrosineMethylphenidate may decrease the antihypertensive activities of Metyrosine.Approved
MibefradilMethylphenidate may decrease the antihypertensive activities of Mibefradil.Withdrawn
MinaprineMinaprine may increase the hypertensive activities of Methylphenidate.Approved
MinoxidilMethylphenidate may decrease the antihypertensive activities of Minoxidil.Approved
MirabegronThe metabolism of Methylphenidate can be decreased when combined with Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Mirtazapine.Approved
MoclobemideMoclobemide may increase the hypertensive activities of Methylphenidate.Approved
MoexiprilMethylphenidate may decrease the antihypertensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methylphenidate.Approved
MoxonidineMethylphenidate may decrease the antihypertensive activities of Moxonidine.Approved
NadololMethylphenidate may decrease the antihypertensive activities of Nadolol.Approved
NaftopidilMethylphenidate may decrease the antihypertensive activities of Naftopidil.Investigational
NebivololMethylphenidate may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NevirapineThe metabolism of Methylphenidate can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypertensive activities of Methylphenidate.Withdrawn
NicardipineMethylphenidate may decrease the antihypertensive activities of Nicardipine.Approved
NicorandilMethylphenidate may decrease the antihypertensive activities of Nicorandil.Approved
NiguldipineMethylphenidate may decrease the antihypertensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Methylphenidate can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineMethylphenidate may decrease the antihypertensive activities of Nilvadipine.Approved
NimodipineMethylphenidate may decrease the antihypertensive activities of Nimodipine.Approved
NisoldipineMethylphenidate may decrease the antihypertensive activities of Nisoldipine.Approved
NitrendipineMethylphenidate may decrease the antihypertensive activities of Nitrendipine.Approved
NitroprussideMethylphenidate may decrease the antihypertensive activities of Nitroprusside.Approved
Nitrous oxideMethylphenidate may increase the hypertensive activities of Nitrous oxide.Approved, Vet Approved
NizatidineNizatidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Methylphenidate.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenidate.Approved, Investigational
OlmesartanMethylphenidate may decrease the antihypertensive activities of Olmesartan.Approved, Investigational
OmapatrilatMethylphenidate may decrease the antihypertensive activities of Omapatrilat.Investigational
OmeprazoleOmeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methylphenidate.Approved
OpipramolThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Opipramol.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Methylphenidate.Investigational
OxprenololMethylphenidate may decrease the antihypertensive activities of Oxprenolol.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.Approved
PanobinostatThe serum concentration of Methylphenidate can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazolePantoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
PargylinePargyline may increase the hypertensive activities of Methylphenidate.Approved
ParoxetineThe metabolism of Methylphenidate can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Methylphenidate can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololMethylphenidate may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentoliniumMethylphenidate may decrease the antihypertensive activities of Pentolinium.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Methylphenidate.Investigational
PerindoprilMethylphenidate may decrease the antihypertensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Methylphenidate.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Methylphenidate.Approved
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Methylphenidate.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Methylphenidate.Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Methylphenidate.Approved
PhenoxybenzamineMethylphenidate may decrease the antihypertensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Methylphenidate.Withdrawn
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Methylphenidate.Approved
PhentolamineMethylphenidate may decrease the antihypertensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Methylphenidate.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methylphenidate.Approved
PinacidilMethylphenidate may decrease the antihypertensive activities of Pinacidil.Withdrawn
PindololMethylphenidate may decrease the antihypertensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methylphenidate.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylphenidate.Approved
PiribedilThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Piribedil.Investigational
PirlindolePirlindole may increase the hypertensive activities of Methylphenidate.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Methylphenidate.Withdrawn
PolythiazideMethylphenidate may decrease the antihypertensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole.Approved, Investigational
PrazosinMethylphenidate may decrease the antihypertensive activities of Prazosin.Approved
PrimidoneThe serum concentration of the active metabolites of Primidone can be increased when Primidone is used in combination with Methylphenidate.Approved, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Methylphenidate.Approved
PropranololMethylphenidate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Methylphenidate.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.Approved
QuinaprilMethylphenidate may decrease the antihypertensive activities of Quinapril.Approved, Investigational
QuinidineThe metabolism of Methylphenidate can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Methylphenidate can be decreased when combined with Quinine.Approved
RabeprazoleRabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Methylphenidate.Investigational
RamiprilMethylphenidate may decrease the antihypertensive activities of Ramipril.Approved
RanitidineRanitidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
RanolazineThe metabolism of Methylphenidate can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypertensive activities of Methylphenidate.Approved
RemikirenMethylphenidate may decrease the antihypertensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate.Approved, Withdrawn
RescinnamineMethylphenidate may decrease the antihypertensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methylphenidate.Approved
RilmenidineMethylphenidate may decrease the antihypertensive activities of Rilmenidine.Investigational
RiociguatMethylphenidate may decrease the antihypertensive activities of Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Methylphenidate.Investigational
RitonavirThe metabolism of Methylphenidate can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Methylphenidate can be decreased when combined with Rolapitant.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Ropinirole.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Rotigotine.Approved
Roxatidine acetateRoxatidine acetate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
SafrazineSafrazine may increase the hypertensive activities of Methylphenidate.Withdrawn
SaprisartanMethylphenidate may decrease the antihypertensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypertensive activities of Methylphenidate.Approved, Investigational, Vet Approved
SelexipagMethylphenidate may decrease the antihypertensive activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Methylphenidate.Approved, Withdrawn
SertralineThe metabolism of Methylphenidate can be decreased when combined with Sertraline.Approved
SevofluraneMethylphenidate may increase the hypertensive activities of Sevoflurane.Approved, Vet Approved
SitaxentanMethylphenidate may decrease the antihypertensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilMethylphenidate may decrease the antihypertensive activities of Spirapril.Approved
StiripentolThe metabolism of Methylphenidate can be decreased when combined with Stiripentol.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate.Approved
TAK-390MRTAK-390MR can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Investigational
TelmisartanMethylphenidate may decrease the antihypertensive activities of Telmisartan.Approved, Investigational
TemocaprilMethylphenidate may decrease the antihypertensive activities of Temocapril.Experimental, Investigational
TerbinafineThe metabolism of Methylphenidate can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerlipressinMethylphenidate may decrease the antihypertensive activities of Terlipressin.Approved, Investigational
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Methylphenidate.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Methylphenidate.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate.Approved
TianeptineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Tianeptine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Methylphenidate.Investigational
TiboloneMethylphenidate may decrease the antihypertensive activities of Tibolone.Approved
TiclopidineThe metabolism of Methylphenidate can be decreased when combined with Ticlopidine.Approved
TicrynafenMethylphenidate may decrease the antihypertensive activities of Ticrynafen.Withdrawn
TimololMethylphenidate may decrease the antihypertensive activities of Timolol.Approved
TipranavirThe metabolism of Methylphenidate can be decreased when combined with Tipranavir.Approved, Investigational
TolazolineMethylphenidate may decrease the antihypertensive activities of Tolazoline.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypertensive activities of Methylphenidate.Approved
TorasemideMethylphenidate may decrease the antihypertensive activities of Torasemide.Approved
TrandolaprilMethylphenidate may decrease the antihypertensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Methylphenidate.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Methylphenidate.Approved
TravoprostMethylphenidate may decrease the antihypertensive activities of Travoprost.Approved
TreprostinilMethylphenidate may decrease the antihypertensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideMethylphenidate may decrease the antihypertensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenidate.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate.Approved, Vet Approved
TrimazosinMethylphenidate may decrease the antihypertensive activities of Trimazosin.Experimental
TrimethaphanMethylphenidate may decrease the antihypertensive activities of Trimethaphan.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.Approved
UnoprostoneMethylphenidate may decrease the antihypertensive activities of Unoprostone.Approved
ValsartanMethylphenidate may decrease the antihypertensive activities of Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Methylphenidate can be decreased when combined with Venlafaxine.Approved
VinpocetineMethylphenidate may decrease the antihypertensive activities of Vinpocetine.Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Methylphenidate.Approved
XylometazolineMethylphenidate may decrease the antihypertensive activities of Xylometazoline.Approved
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Methylphenidate.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenidate.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Take on empty stomach: 1 hour before or 2 hours after meals.
References
Synthesis Reference

DrugSyn.org

US2512572
General References
  1. Keating GM, McClellan K, Jarvis B: Methylphenidate (OROS formulation). CNS Drugs. 2001;15(6):495-500; discussion 501-3. [PubMed:11524026 ]
  2. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R: A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006 Dec;16(6):687-98. [PubMed:17201613 ]
  3. Fone KC, Nutt DJ: Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005 Feb;5(1):87-93. [PubMed:15661631 ]
  4. Sharma RP, Javaid JI, Pandey GN, Easton M, Davis JM: Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone. Psychiatry Res. 1990 Apr;32(1):9-17. [PubMed:2190251 ]
  5. Shults T, Kownacki AA, Woods WE, Valentine R, Dougherty J, Tobin T: Pharmacokinetics and behavioral effects of methylphenidate in Thoroughbred horses. Am J Vet Res. 1981 May;42(5):722-6. [PubMed:7258793 ]
External Links
ATC CodesN06BA04
AHFS Codes
  • 28:20.92
PDB EntriesNot Available
FDA labelDownload (178 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9663
Caco-2 permeable+0.6564
P-glycoprotein substrateSubstrate0.5466
P-glycoprotein inhibitor INon-inhibitor0.7964
P-glycoprotein inhibitor IINon-inhibitor0.9601
Renal organic cation transporterInhibitor0.532
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5985
CYP450 1A2 substrateNon-inhibitor0.592
CYP450 2C9 inhibitorNon-inhibitor0.897
CYP450 2D6 inhibitorNon-inhibitor0.5245
CYP450 2C19 inhibitorNon-inhibitor0.9265
CYP450 3A4 inhibitorNon-inhibitor0.8539
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9328
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9648
BiodegradationNot ready biodegradable0.5759
Rat acute toxicity2.7718 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8466
hERG inhibition (predictor II)Non-inhibitor0.7491
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shire development inc
  • Ucb inc
  • Novartis pharmaceuticals corp
  • Mallinckrodt inc
  • Tris pharma inc
  • Ortho mcneil janssen pharmaceutical inc
  • Able laboratories inc
  • Actavis elizabeth llc
  • Watson laboratories inc
  • Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseOral15 mg/1
Capsule, extended releaseOral10 mg
Capsule, extended releaseOral15 mg
Capsule, extended releaseOral20 mg
Capsule, extended releaseOral30 mg
Capsule, extended releaseOral40 mg
Capsule, extended releaseOral50 mg
Capsule, extended releaseOral60 mg
Capsule, extended releaseOral80 mg
Tablet, extended releaseOral18 mg
Tablet, extended releaseOral27 mg
Tablet, extended releaseOral36 mg
Tablet, extended releaseOral54 mg
PatchTransdermal10 mg/9h
PatchTransdermal15 mg/9h
PatchTransdermal20 mg/9h
PatchTransdermal30 mg/9h
Tablet, extended releaseOral20 mg/1
SolutionOral10 mg/5mL
SolutionOral5 mg/5mL
TabletOral18 mg/1
Tablet, chewableOral10 mg/1
Tablet, chewableOral2.5 mg/1
Tablet, chewableOral5 mg/1
Tablet, extended releaseOral18 mg/1
Tablet, extended releaseOral27 mg/1
Tablet, extended releaseOral36 mg/1
Tablet, extended releaseOral54 mg/1
Capsule, extended releaseOral50 mg/1
Tablet, extended releaseOral10 mg/1
CapsuleOral10 mg/1
CapsuleOral20 mg/1
CapsuleOral30 mg/1
CapsuleOral40 mg/1
CapsuleOral50 mg/1
CapsuleOral60 mg/1
TabletOral27 mg/1
TabletOral36 mg/1
TabletOral54 mg/1
Tablet, film coated, extended releaseOral20 mg/1
TabletOral10.00 mg
TabletOral20.00 mg
TabletOral5.00 mg
TabletOral10 mg
TabletOral20 mg
TabletOral5 mg
Tablet, chewable, extended releaseOral20 mg/1
Tablet, chewable, extended releaseOral30 mg/1
Tablet, chewable, extended releaseOral40 mg/1
Powder, for suspensionOral300 mg/60mL
Powder, for suspensionOral600 mg/120mL
Powder, for suspensionOral750 mg/150mL
Powder, for suspensionOral900 mg/180mL
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
Capsule, extended releaseOral10 mg/1
Capsule, extended releaseOral20 mg/1
Capsule, extended releaseOral30 mg/1
Capsule, extended releaseOral40 mg/1
Capsule, extended releaseOral60 mg/1
Tablet, extended releaseOral20 mg
Prices
Unit descriptionCostUnit
Daytrana 30 15 mg/9hr Patches Box175.64USD box
Daytrana 30 30 mg/9hr Patches Box174.73USD box
Daytrana 30 10 mg/9hr Patches Box172.78USD box
Daytrana 30 20 mg/9hr Patches Box168.72USD box
Methylphenidate hcl powder44.62USD g
Concerta er 54 mg tablet25.45USD tablet
Concerta er 36 mg tablet23.38USD tablet
Concerta er 27 mg tablet22.65USD tablet
Concerta er 18 mg tablet22.11USD tablet
Metadate cd 50 mg capsule7.08USD capsule
Metadate cd 60 mg capsule7.02USD capsule
Concerta 54 mg Controlled Release Tabs6.18USD tab
Metadate cd 40 mg capsule5.77USD capsule
Concerta 36 mg Controlled Release Tabs5.72USD tab
Focalin xr 30 mg capsule5.42USD capsule
Focalin XR 20 mg 24 Hour Capsule5.31USD capsule
Daytrana 10 mg/9 hr patch5.16USD patch
Daytrana 15 mg/9 hr patch5.16USD patch
Daytrana 20 mg/9 hour patch5.16USD patch
Daytrana 30 mg/9 hour patch5.16USD patch
Focalin xr 15 mg capsule5.16USD capsule
Focalin xr 20 mg capsule5.16USD capsule
Focalin XR 30 mg 24 Hour Capsule5.15USD capsule
Focalin xr 10 mg capsule5.02USD capsule
Concerta 18 mg Controlled Release Tabs5.0USD tab
Concerta 27 mg Controlled Release Tabs5.0USD tab
Focalin XR 10 mg 24 Hour Capsule4.96USD capsule
Focalin xr 5 mg capsule4.95USD capsule
Concerta 54 mg tablet sa4.91USD tablet
Focalin XR 15 mg 24 Hour Capsule4.89USD capsule
Focalin XR 5 mg 24 Hour Capsule4.83USD capsule
Ritalin la 40 mg capsule4.55USD capsule
Concerta 36 mg tablet sa4.51USD tablet
Ritalin la 30 mg capsule4.43USD capsule
Ritalin LA 10 mg 24 Hour Capsule4.42USD capsule
Ritalin LA 20 mg 24 Hour Capsule4.42USD capsule
Ritalin LA 30 mg 24 Hour Capsule4.42USD capsule
Ritalin LA 40 mg 24 Hour Capsule4.42USD capsule
Concerta 27 mg tablet sa4.37USD tablet
Ritalin la 10 mg capsule4.33USD capsule
Ritalin la 20 mg capsule4.33USD capsule
Concerta 18 mg tablet sa4.27USD tablet
Metadate cd 20 mg capsule4.24USD capsule
Metadate cd 30 mg capsule4.24USD capsule
Metadate cd 10 mg capsule4.2USD capsule
Methylphenidate er 10 mg tablet3.24USD tablet
Ritalin SR 20 mg Controlled Release Tabs3.0USD tab
Ritalin sr 20 mg tablet2.67USD tablet
Ritalin 20 mg tablet1.87USD tablet
Focalin 10 mg tablet1.7USD tablet
Ritalin 5 mg tablet1.42USD tablet
Metadate er 20 mg tablet1.32USD tablet
Methylin ER 20 mg Controlled Release Tabs1.3USD tab
Ritalin 10 mg tablet1.29USD tablet
Metadate er 10 mg tablet sa1.28USD tablet
Focalin 5 mg tablet1.26USD tablet
Methylphenidate HCl CR 20 mg Controlled Release Tabs1.2USD tab
Methylin er 20 mg tablet1.12USD tablet
Methylphenidate HCl 20 mg tablet1.05USD tablet
Methylin ER 10 mg1.0USD tab
Methylphenidate HCl 10 mg tablet0.95USD tablet
Methylphenidate HCl 5 mg tablet0.94USD tablet
Methylin er 10 mg tablet0.84USD tablet
Focalin 2.5 mg tablet0.76USD tablet
Methylin 20 mg tablet0.69USD tablet
Methylphenidate 20 mg tablet0.69USD tablet
Ritalin 20 mg Tablet0.67USD tablet
Ritalin Sr 20 mg Extended-Release Tablet0.67USD tablet
Methylin 10 mg tablet0.48USD tablet
Methylphenidate 10 mg tablet0.48USD tablet
Ritalin 10 mg Tablet0.38USD tablet
Apo-Methylphenidate 20 mg Tablet0.37USD tablet
Apo-Methylphenidate Sr 20 mg Extended-Release Tablet0.37USD tablet
Pms-Methylphenidate 20 mg Tablet0.37USD tablet
Sandoz Methylphenidate 20 mg Extended-Release Tablet0.37USD tablet
Methylin 5 mg tablet0.33USD tablet
Methylphenidate 5 mg tablet0.33USD tablet
Apo-Methylphenidate 10 mg Tablet0.17USD tablet
Pms-Methylphenidate 10 mg Tablet0.17USD tablet
Pms-Methylphenidate 5 mg Tablet0.1USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2264852 No2005-11-012017-09-16Canada
CA2355644 No2009-01-202019-12-17Canada
US5837284 No1995-12-042015-12-04Us
US5958446 No1992-12-122012-12-12Us
US6210705 No1998-09-302018-09-30Us
US6228398 No1999-11-012019-11-01Us
US6344215 No2000-10-272020-10-27Us
US6348211 No1998-09-302018-09-30Us
US6419960 No1999-12-162019-12-16Us
US6635284 No1995-12-042015-12-04Us
US6919373 Yes1998-01-312018-01-31Us
US6930129 Yes1998-01-312018-01-31Us
US7083808 No1999-12-162019-12-16Us
US7247318 No1999-12-162019-12-16Us
US7431944 No1995-12-042015-12-04Us
US7438930 No1999-12-162019-12-16Us
US7691880 No2004-10-072024-10-07Us
US8062667 No2009-03-292029-03-29Us
US8163798 Yes1998-01-312018-01-31Us
US8202537 No2007-03-152027-03-15Us
US8287903 No2011-02-152031-02-15Us
US8465765 No2011-02-152031-02-15Us
US8563033 No2011-02-152031-02-15Us
US8580310 No1999-12-162019-12-16Us
US8629179 Yes1998-01-312018-01-31Us
US8632802 No2005-10-072025-10-07Us
US8778390 No2011-02-152031-02-15Us
US8956649 No2011-02-152031-02-15Us
US8999386 No2013-04-142033-04-14Us
US9000038 Yes1998-01-312018-01-31Us
US9029416 No1997-07-312017-07-31Us
US9034370 No2005-10-072025-10-07Us
US9040083 No2011-02-152031-02-15Us
US9066869 No1999-12-162019-12-16Us
US9144549 No1997-07-312017-07-31Us
US9295642 No2013-08-142033-08-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point224-226 °CNot Available
water solubility1255mg/LNot Available
logP0.20HANSCH,C ET AL. (1995), pH 7.2
pKa8.77SANGSTER,J (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.182 mg/mLALOGPS
logP1.47ALOGPS
logP2.25ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)9.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity66.73 m3·mol-1ChemAxon
Polarizability26.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.79 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-9100000000-1a9c5badbee827946da1View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetic acid derivatives
Direct ParentPhenylacetic acid derivatives
Alternative Parents
Substituents
  • Phenylacetate
  • Aralkylamine
  • Piperidine
  • Methyl ester
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang GJ, Logan J, Ding YS, Franceschi D, Gifford A, Morgan A, Pappas N, King P: Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse. 1999 Jan;31(1):59-66. [PubMed:10025684 ]
  2. Wayment HK, Deutsch H, Schweri MM, Schenk JO: Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists? J Neurochem. 1999 Mar;72(3):1266-74. [PubMed:10037500 ]
  3. Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7. [PubMed:10199939 ]
  4. Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, Gatley SJ, Logan J, Wong C, Gifford A, Ding YS, Hitzemann R, Pappas N: Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci. 1999;65(1):PL7-12. [PubMed:10403500 ]
  5. Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93. [PubMed:10414438 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  8. Viggiano D, Vallone D, Sadile A: Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling. Neural Plast. 2004;11(1-2):97-114. [PubMed:15303308 ]
  9. Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. doi: 10.1124/jpet.108.141713. Epub 2008 Aug 12. [PubMed:18698001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Yang L, Wang YF, Li J, Faraone SV: Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry. 2004 Sep;43(9):1154-8. [PubMed:15322419 ]
  2. Williard RL, Middaugh LD, Zhu HJ, Patrick KS: Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol. 2007 Feb;18(1):39-51. [PubMed:17218796 ]
  3. Chuhan YS, Taukulis HK: Impairment of single-trial memory formation by oral methylphenidate in the rat. Neurobiol Learn Mem. 2006 Mar;85(2):125-31. Epub 2005 Oct 24. [PubMed:16246598 ]
  4. Gray JD, Punsoni M, Tabori NE, Melton JT, Fanslow V, Ward MJ, Zupan B, Menzer D, Rice J, Drake CT, Romeo RD, Brake WG, Torres-Reveron A, Milner TA: Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci. 2007 Jul 4;27(27):7196-207. [PubMed:17611273 ]
  5. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE: Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci. 2001 Feb 15;21(4):1413-9. [PubMed:11160413 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  7. Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. doi: 10.1124/jpet.108.141713. Epub 2008 Aug 12. [PubMed:18698001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7. [PubMed:10199939 ]
  2. Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93. [PubMed:10414438 ]
  3. Stehouwer JS, Jarkas N, Zeng F, Voll RJ, Williams L, Owens MJ, Votaw JR, Goodman MM: Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem. 2006 Nov 16;49(23):6760-7. [PubMed:17154506 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Carboxylic ester hydrolase activity
Specific Function:
Not Available
Gene Name:
CES1A1a
Uniprot ID:
Q6LAP9
Molecular Weight:
1908.25 Da
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:54